Transforming the lives of airways disease patients

Vectura is an industry-leading device & formulation business for inhaled airways disease.



  • Recurring revenues driven by on-market partnered products, underpinned by a robust pipeline
  • Consilium appointed to provide strategic IR and communications guidance to enlarged Vectura Group post-merger with Skyepharma in 2016


merger with Skyepharma


Our strategy

  • Supporting implementation of international IR and profile-raising strategy
  • Review of corporate materials including website, key messaging, presentation, Q&A
  • Media engagement to position Vectura as new international ‘respiratory powerhouse’ post-merger
  • Media/analyst messaging management around a regulatory setback for a key programme
  • Ongoing simplification of the story and strategy, including development of additional suggested materials



  • Simplification of investment case – enhanced focus on core strengths and clear guidance